



430 – 580 Hornby Street,  
Vancouver BC  
V6C 3B6  
Phone: (604) 674-2191

Email: [info@supreme.ca](mailto:info@supreme.ca)  
Website: [www.supreme.ca](http://www.supreme.ca)

*Listed on the CSE under the symbol ("SL")*

---

**NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.**

**SUPREME COMPLETES PRIVATE PLACEMENT FOR AGGREGATE TOTAL OF \$1.78M**

**November 17, 2014, Vancouver, BC** – Supreme Pharmaceuticals Inc. ("**Supreme**" or the "**Company**") (SL:CSE) is pleased to announce that it has closed the final tranche of its previously announced unit financing for gross proceeds of \$815,893.44 (the "**Financing**"). At the final closing, Supreme issued 2,549,667 units (comprised of 2,549,667 common shares of the Company ("**Common Shares**") and 1,274,834 Common Share purchase warrants ("**Warrants**")) at a price of \$0.32 per unit. Each Warrant is exercisable for one Common Share at a price of \$0.50 per share prior to November 17, 2016, subject to an accelerated expiry period upon 30-days notice by the Company to the subscriber, if the Common Shares trade at or above \$0.70 for any five (5) day period during the term of the Warrants. In aggregate, total gross proceeds raised from the first and second closings totalled \$1,781,642.24 through the issuance of 5,567,632 Common Shares and 2,783,816 Warrants.

“Having raised almost double the proceeds that we initially sought when we announced our raise just three weeks ago, we’re pleased with the positive response we’ve had, and extremely gratified at the investment community’s ongoing interest in Supreme”, stated a director of the company. “With this raise now finalized, we have a strong balance sheet and are well-positioned to continue executing on our long-term growth strategy.”

The Company paid aggregate finder's fees of \$21,769.60 and issued 68,030 Warrants to certain arm's-length parties in the connection with the subscriptions of certain subscribers who participated in the Financing.

The Common Shares and Warrants issued pursuant to the final tranche of the Financing are subject to a hold period that expires March 18, 2015. Following closing, Supreme has 76,031,197 Common Shares issued and outstanding.

The Company intends to use the aggregate proceeds of the Financing for the continuing development of the Company's Kincardine facility and general working capital purposes.

**Contact Information**

**Investor Relations**

**430 – 580 Hornby Street, Vancouver BC**

**V6C 3B6**

**Phone: (604) 674-2191**

**Email: [info@supreme.ca](mailto:info@supreme.ca)**

**Website: [www.supreme.ca](http://www.supreme.ca)**

## **FORWARD-LOOKING INFORMATION**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the use of proceeds of the Financing, as well as the Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan following the issuance of the required licenses by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.